Mode
Text Size
Log in / Sign up
N/A N=23 Randomized Treatment

Support for Perinatal Adherence and Depression

Human Immunodeficiency Virus · Depression

Enrolled (actual)
23
Serious AEs
0.0%
Results posted
Dec 2021
Primary outcome: Primary: Adherence to Antiretroviral Therapy Per Self-Report — 85.3; 79.0; 92.8; 77.8 percentage of self-reported adherence — p=0.11

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Integrating Nuanced Support for Perinatal adherence and Depression (Behavioral)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
Massachusetts General Hospital
Primary completion
Mar 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Adherence to Antiretroviral Therapy Per Self-Report
85.3; 79.0; 92.8; 77.8; 88.7; 89.2 0.11
PRIMARY
Adherence to Antiretroviral Therapy Per MEMS Caps
99.4; 92.9; 98.6; 100.0; 92.8; 85.7 < 0.05 sig
PRIMARY
Level of Depressive Symptoms Per Edinburgh Postnatal Depression Scale (EPDS)
20.8; 20.3; 1.2; 11.8; 2.1; 6.5 < 0.005 sig
PRIMARY
Number of Participants With Depressive Symptoms Per MINI - Meeting Criteria for MDD
12; 7; 0; 2; 0; 1
SECONDARY
Level of Stigma Per HIV/AIDS Stigma Instrument (HASI-P)
14.3; 24.3; 6.3; 12.8; 2.5; 12.5 < 0.05 sig
SECONDARY
Level of Social Support Per Duke-UNC Functional Social Support Questionnaire
33.9; 27.7; 35.3; 28.0; 36.4; 36.5 < 0.05 sig

Summary

The main aim was to conduct a pilot field test of a group-based depression and adherence counseling intervention with HIV-infected women in the perinatal period. Participants were HIV-infected women living in KwaZulu-Natal, South Africa.

Eligibility Criteria

Inclusion Criteria

  • Currently pregnant
  • HIV-infected and diagnosed with HIV during the index pregnancy
  • Meet criteria for a major depressive episode
  • Currently on antiretroviral therapy
  • Receiving antenatal care at PMMH Gateway clinic
  • Primary language English or isiZulu
  • Access to a phone and willing to give researchers permission to reach them via phone
  • Resident of Umlazi

Exclusion Criteria

  • Unable or unwilling to provide informed consent
  • Active untreated, major mental illness (untreated psychosis, bipolar disorder, dementia, or active suicidality) that would interfere with study participation
  • Less than 18 years of age
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03069417). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search